A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function

Trial Profile

A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications Mesothelioma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Epizyme
  • Most Recent Events

    • 13 Mar 2018 Primary endpoint (Disease control rate (DCR) at 12 weeks: greater than or equal to 35 percent) has been met, According to an Epizyme media release.
    • 12 Mar 2018 According to an Epizyme media release, company plans to present data from this study at a medical meeting to communicate next steps for this tumor type in mid-2018.
    • 04 Aug 2017 According to an Epizyme media release, the company expects to report data from this study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top